Restart Life Sciences Corp. NMLSF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 143.93% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 143.93% | -- | |||
| Cost of Revenue | 173.72% | -- | |||
| Gross Profit | 108.85% | -- | |||
| SG&A Expenses | 199.10% | 19.84% | |||
| Depreciation & Amortization | 131.03% | 866.67% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 190.11% | 46.53% | |||
| Operating Income | -210.15% | -2.26% | |||
| Income Before Tax | -209.00% | -110.73% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -209.00% | -110.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -209.00% | -110.73% | |||
| EBIT | -210.15% | -2.26% | |||
| EBITDA | -210.94% | -1.99% | |||
| EPS Basic | -188.10% | -44.83% | |||
| Normalized Basic EPS | -184.62% | 27.78% | |||
| EPS Diluted | -97.26% | -151.72% | |||
| Normalized Diluted EPS | -184.62% | 27.78% | |||
| Average Basic Shares Outstanding | 7.49% | 43.85% | |||
| Average Diluted Shares Outstanding | 7.49% | 43.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||